Publication & Citation Trends
Most Cited Works
Publications
125 total
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial PDF
Cited by 268
OpenAlex
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial PDF
Cited by 223
OpenAlex
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial PDF
Cited by 773
OpenAlex
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort PDF
Cited by 323
OpenAlex
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study PDF
Cited by 336
OpenAlex
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study PDF
Cited by 177
OpenAlex
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study PDF
Cited by 507
OpenAlex
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial PDF
Cited by 1,250
OpenAlex
Research Topics
Cancer Immunotherapy and Biomarkers
(80)
CAR-T cell therapy research
(46)
Renal cell carcinoma treatment
(28)
Immunotherapy and Immune Responses
(19)
Melanoma and MAPK Pathways
(18)
Frequent Co-Authors
Affiliations
Cedars-Sinai Medical Center
Indiana University Health
City Of Hope National Medical Center
Seattle Cancer Care Alliance
Carolinas Healthcare System